Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2

Conditions

Multiple Myeloma 161Recurrence 30Neoplasms, Plasma Cell 11Neoplasms 7Lymphoma, Mantle-Cell 7Paraproteinemias 6Lymphoma, Follicular 5Hematologic Neoplasms 5Lymphoma, Non-Hodgkin 4Immunoglobulin Light-chain Amyloidosis 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Immunoproliferative Disorders 3Immune System Diseases 3Hematologic Diseases 3Carcinoma, Non-Small-Cell Lung 3Blood Protein Disorders 3Plasmacytoma 2Neoplasms by Histologic Type 2Neoplasm Metastasis 2Lymphoproliferative Disorders 2Lymphoma, B-Cell 2Leukemia, Plasma Cell 2Leukemia, Myeloid, Acute 2Hemostatic Disorders 2Hemorrhagic Disorders 2Bone Marrow Neoplasms 2Amyloidosis 2Wilms Tumor 1

Interventions

Dexamethasone 3filanesib 2Steroids 2Injections, Subcutaneous 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Bortezomib 2venetoclax 1liposomal doxorubicin 1Proteasome Inhibitors 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Plasma Cell × Bortezomib × Clear all
NCT01248923 2020-09-30

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Array BioPharma

Phase 1 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

NCT01328236 2011-09-22

Bortezomib

Clinical Service, China

Phase 2 Unknown
20 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡